Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor
and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such
as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving sunitinib together with
tamoxifen and cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving sunitinib
together with tamoxifen and cisplatin works in treating patients with high-risk ocular
melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
San Diego Pacific Oncology & Hematology Associates